Interestingly, the orally active antagonists SCH‐527123 and SCH‐479833, which target CXCR2 and CXCR1, prevent neovascularization and increase apoptosis, thereby inhibiting CRC liver metastasis [105]. This evidence concerns the gene CXCR2 and colorectal carcinoma.